404 related articles for article (PubMed ID: 15998706)
1. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.
Sawathiparnich P; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2002 Feb; 87(2):448-52. PubMed ID: 11836266
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
4. The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters.
Kaşifoğlu T; Yalçin AU
Anadolu Kardiyol Derg; 2006 Jun; 6(2):143-7. PubMed ID: 16766279
[TBL] [Abstract][Full Text] [Related]
5. Effect of spironolactone on impaired fibrinolysis of hypertensive patients.
Yalcin AI; Dincer M; Aslan V; Gulbas Z
Kidney Blood Press Res; 2002; 25(4):260-4. PubMed ID: 12424430
[TBL] [Abstract][Full Text] [Related]
6. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Brown NJ; Kumar S; Painter CA; Vaughan DE
Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
[TBL] [Abstract][Full Text] [Related]
9. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
Jeunemaitre X; Charru A; Chatellier G; Degoulet P; Julien J; Plouin PF; Corvol P; Ménard J
Am J Cardiol; 1988 Nov; 62(16):1072-7. PubMed ID: 3189169
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
11. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition.
Brown NJ; Muldowney JA; Vaughan DE
Hypertension; 2006 Mar; 47(3):441-8. PubMed ID: 16432054
[TBL] [Abstract][Full Text] [Related]
12. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
13. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
14. [Properties and indications of potassium-sparing diuretics].
Rorive G; Krzesinski JM
Rev Med Liege; 1986 May; 41(9):330-6. PubMed ID: 3523669
[No Abstract] [Full Text] [Related]
15. Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination.
Douglas JG; Hollifield JW; Liddle GW
JAMA; 1974 Feb; 227(5):518-21. PubMed ID: 4589187
[No Abstract] [Full Text] [Related]
16. Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen W; Wilson T
Clin Invest Med; 1998 Jun; 21(3):142-50. PubMed ID: 9627768
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic function in diuretic-induced volume depletion.
Lottermoser K; Hertfelder HJ; Vetter H; Düsing R
Am J Hypertens; 2000 Apr; 13(4 Pt 1):359-63. PubMed ID: 10821336
[TBL] [Abstract][Full Text] [Related]
18. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Stankiewicz A; Mikita J; Aleksiejczuk M; Marcinczyk N; Szemraj J; Chabielska E
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980144
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]